A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed or Refractory Waldenstrom's Macroglobulinemia

被引：0
|
作者：
Ghobrial, Irene M.
Gertz, Morie A.
LaPlant, Betsy
Camoriano, John [3 ]
Hayman, Suzanne R.
Lacy, Martha Q.
Chuma, Stacey
Sheehy, Patricia [1 ]
Harris, Brianna
Leduc, Renee
Rourke, Meghan
Ansell, Stephen M. [2 ]
DeAngelo, Daniel J. [1 ]
Dispenzieri, Angela
Bergsagel, Leif [3 ]
Reeder, Craig B. [3 ]
Anderson, Kenneth C.
Richardson, Paul
Treon, Steven
Witzig, Thomas E. [2 ]
机构：
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[2] Mayo Clin, Coll Med, Rochester, MN USA
[3] Mayo Clin, Scottsdale, AZ USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：244 / 244
页数：1
相关论文
共 50 条
  • [1] Phase II trial of the oral mTOR inhibitor RAD001 (everolimus) in relapsed and/or refractory Waldenstrom Macroglobulinemia: Preliminary results
    Ghobrial, Irene M.
    Leduc, Renee
    Nelson, Marybeth
    Leleu, Xavier
    Jacobsen, Eric
    LaCasce, Ann
    DeAngelo, Daniel
    Fisher, David
    Brown, Jennifer R.
    Schlossman, Robert
    Warren, Diane
    Soumerai, Jacob
    O'Connor, Kelly
    Munshi, Nikhil
    Richardson, Paul
    Anderson, Kenneth C.
    Witzig, Thomas E.
    Treon, Steven P.
    BLOOD, 2007, 110 (11) : 195B - 196B
  • [2] Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia
    Ghobrial, Irene M.
    Witzig, Thomas E.
    Gertz, Morie
    LaPlant, Betsy
    Hayman, Suzanne
    Camoriano, John
    Lacy, Martha
    Bergsagel, P. Leif
    Chuma, Stacey
    DeAngelo, Daniel
    Treon, Steven P.
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (03) : 237 - 242
  • [3] Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom macroglobulinemia.
    Ghobrial, Irene M.
    Gertz, Morie A.
    LaPlant, Betsy
    Camoriano, John Kelly
    Hayman, Suzanne R.
    Lacy, Martha
    Chuma, Stacey
    Harris, Brianna
    Boswell, Erica
    Banwait, Ranjit
    Sheehy, Patricia
    Ansell, Stephen Maxted
    DeAngelo, Daniel J.
    Dispenzieri, Angela
    Bergsagel, Leif
    Reeder, Craig B.
    Anderson, Kenneth Carl
    Richardson, Paul Gerard Guy
    Treon, Steven P.
    Witzig, Thomas E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Phase II trial of the oral mTOR inhibitor everolimus (RAD001) for patients with relapsed or refractory lymphoma
    Johnston, P. B.
    Ansell, S. M.
    Colgan, J. P.
    Habermann, T. M.
    Inwards, D. J.
    Markovic, S. N.
    Micallef, I. N.
    Porrata, L. F.
    LaPlant, B. R.
    Geyer, S. M.
    Witzig, T. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia
    Ghobrial, Irene M.
    Redd, Robert Allyn
    Matous, Jeffrey
    Armand, Philippe
    Boswell, Erica N.
    Chuma, Stacey
    Noonan, Kimberly
    MacNabb, Megan H.
    Banwait, Ranjit
    Hanlon, Courtney
    Leblebjian, Houry
    Warren, Diane
    Castillo, Jorge J.
    Laubach, Jacob P.
    Paba-Prada, Claudia E.
    Anderson, Kenneth C.
    Richardson, Paul G.
    Weller, Edie A.
    Treon, Steven P.
    BLOOD, 2014, 124 (21)
  • [6] RAD001: Phase II Trial in Relapsed/Refractory Waldenstrom Macroglobulinemia, the DFCI Experience
    Ghobrial, I. M.
    Roccaro, A. M.
    Chuma, S.
    Sam, A. P.
    Leduc, R.
    Nelson, M.
    O'Connor, K.
    Harris, B.
    Soumerai, J.
    Warren, D.
    Jacobsen, E.
    DeAngelo, D.
    Berg, W.
    Anderson, K. C.
    Richardson, P. G.
    Witzig, T. E.
    Treon, S. P.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S82 - S83
  • [7] Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience.
    Ghobrial, Irene M.
    Chuma, Stacey
    Sam, Amy
    Leduc, Renee
    Nelson, Marybeth
    O'Connor, Kelly
    Harris, Brianna
    Soumerai, Jacob
    Warren, Diane
    Jacobsen, Eric
    DeAngelo, Daniel
    Anderson, Kenneth C.
    Richardson, Paul G.
    Witzig, Thomas E.
    Treon, Steven P.
    BLOOD, 2008, 112 (11) : 372 - 372
  • [8] Prospective, Multicenter Study of the MTOR Inhibitor Everolimus (RAD001) As Primary Therapy in Waldenstrom's Macroglobulinemia
    Treon, Steven P.
    Tripsas, Christina K.
    Ioakimidis, Leukothea
    Warren, Diane
    Patterson, Christopher
    Heffner, Leonard
    Eradat, Herbert
    Gregory, Stephanie A.
    Thomas, Sheeba
    Advani, Ranjana
    Baz, Rachid
    Badros, Ashraf Z.
    Matous, Jeffrey
    Anderson, Kenneth C.
    Ghobrial, Irene M.
    BLOOD, 2011, 118 (21) : 1273 - 1274
  • [9] Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenstrom Macroglobulinemia
    Ghobrial, Irene M.
    Gertz, Morie
    LaPlant, Betsy
    Camoriano, John
    Hayman, Suzanne
    Lacy, Martha
    Chuma, Stacey
    Harris, Brianna
    Leduc, Renee
    Rourke, Meghan
    Ansell, Stephen M.
    DeAngelo, Daniel
    Dispenzieri, Angela
    Bergsagel, Leif
    Reeder, Craig
    Anderson, Kenneth C.
    Richardson, Paul G.
    Treon, Steven P.
    Witzig, Thomas E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (08) : 1408 - 1414
  • [10] A phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed aggressive non-hodgkin lymphoma (NHL)
    Gornet, Michel K.
    Habermann, Thomas M.
    Ansell, Stephen M.
    Micallef, Ivana N.
    Porrata, Luis F.
    Johnston, Patrick B.
    Maurer, Matthew J.
    LaPlant, Betsy
    Kabat, Brian
    Inwards, David J.
    Colgan, Joseph P.
    Call, Timothy
    Markovic, Svetomir
    Zent, Clive S.
    Zeldenrust, Steven R.
    Tun, Han W.
    Witzig, Thomas E.
    BLOOD, 2007, 110 (11) : 44A - 44A
12345